Giacomo Chiesi currently serves as Head of Global Rare Diseases at the Chiesi Group. He is based in Boston, Massachusetts.

Previously, Giacomo served as Head of Global Corporate Development. In his tenure with the Chiesi Group he has directly structured and executed 25 deals with over $3B in value ranging from sell-side to buy-side M&A, in- and out-licensing, and spin-outs. He serves on the Board of the Company.

In 2014, he founded Chiesi Ventures as a joint venture with Pappas Capital and is the fund Managing Partner. He serves as a Board Member or Observer on the Boards of Sentien Biotech and and Minoryx Therapeutics and was previously on the boards of Glycomine and Aura Bioscience.

In 2021, he was elected to the board of directors of the Biotechnology Innovation Organisation (BIO), in the Emerging Companies Section (ECS).

Before going back to the Chiesi Group, Giacomo was a consultant with Bain & Co, where he led teams in a variety of assignments including due diligence, restructuring and strategy projects for consumer goods and information technology companies in different countries.

Previously he was with Accenture where he led large teams in outsourcing projects across Europe and the US for clients in transportation and retail.

Giacomo earned a M.Sc. degree Magna cum Laude in Telecommunications Engineering from the University of Parma, Italy, and an MBA from the University of Chicago Booth School of Business with concentrations in Entrepreneurship, Economics and Finance.